Note to editors: Silicon Laboratories, Silicon Labs and the Silicon Labs logo are trademarks of Silicon Laboratories Inc. All other product names noted herein may be trademarks of their respective holders.
Silicon Laboratories Inc. Condensed Consolidated Statements of Income (In thousands, except per share data) (Unaudited) |
||||||||||||||||
Three Months Ended | Nine Months Ended | |||||||||||||||
September 28,
2013 |
September 29,
2012 |
September 28,
2013 |
September 29,
2012 |
|||||||||||||
Revenues | $ | 146,933 | $ | 149,461 | $ | 433,851 | $ | 410,833 | ||||||||
Cost of revenues | 58,772 | 62,968 | 169,545 | 166,442 | ||||||||||||
Gross margin | 88,161 | 86,493 | 264,306 | 244,391 | ||||||||||||
Operating expenses: | ||||||||||||||||
Research and development | 40,662 | 34,768 | 115,631 | 101,943 | ||||||||||||
Selling, general and administrative | 37,009 | 24,495 | 98,519 | 82,075 | ||||||||||||
Operating expenses | 77,671 | 59,263 | 214,150 | 184,018 | ||||||||||||
Operating income | 10,490 | 27,230 | 50,156 | 60,373 | ||||||||||||
Other income (expense): | ||||||||||||||||
Interest income | 129 | 243 | 616 | 1,103 | ||||||||||||
Interest expense | (813 | ) | (234 | ) | (2,486 | ) | (299 | ) | ||||||||
Other income (expense), net | (23 | ) | (161 | ) | 39 | 807 | ||||||||||
Income before income taxes | 9,783 | 27,078 | 48,325 | 61,984 | ||||||||||||
Provision for income taxes | 3,252 | 17,054 | 9,148 | 17,131 | ||||||||||||
Net income |
$ | 6,531 | $ | 10,024 | $ | 39,177 | $ | 44,853 | ||||||||
Earnings per share: | ||||||||||||||||
Basic | $ | 0.15 | $ | 0.24 | $ | 0.92 | $ | 1.06 | ||||||||
Diluted | $ | 0.15 | $ | 0.24 | $ | 0.90 | $ | 1.04 | ||||||||
Weighted-average common shares outstanding: | ||||||||||||||||
Basic | 42,684 | 41,735 | 42,477 | 42,279 | ||||||||||||
Diluted | 43,922 | 42,520 | 43,437 | 43,261 |
Unaudited Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands, except per share data) |
|||||||||||||||||||||||||
Non-GAAP Income
|
Three Months Ended
September 28, 2013 |
||||||||||||||||||||||||
GAAP
|
GAAP
|
Stock
|
Intangible
|
Termination
|
Acquisition
|
Non-GAAP
|
Non-GAAP
|
||||||||||||||||||
Revenues | $ | 146,933 | |||||||||||||||||||||||
Gross margin | 88,161 | 60.0 | % | $ | 269 | $ | 390 | $ | -- | $ | 955 | $ | 89,775 | 61.1 | % | ||||||||||
Research and
development |
40,662 | 27.7 | % | 3,729 | 3,217 | -- | -- |
33,716 |
22.9 | % | |||||||||||||||
Selling, general and administrative |
37,009 |
25.2 |
% |
4,622 | 729 | 291 |
1,604 |
29,763 |
20.3 | % | |||||||||||||||
Operating income | 10,490 | 7.1 | % | 8,620 | 4,336 | 291 | 2,559 | 26,296 | 17.9 | % | |||||||||||||||
Non-GAAP Diluted Earnings Per Share |
Three Months Ended
September 28, 2013 |
||||||||||||||||||||||||
GAAP
|
Stock
|
Intangible
|
Termination
|
Acquisition
|
Non-GAAP
|
||||||||||||||||||||
Net income | $ | 6,531 | $ | 7,716 | $ | 2,986 | $ | 291 | $ | 2,292 | $ | 19,816 | |||||||||||||
Diluted shares outstanding |
|
43,922 | -- | -- | -- | -- | 43,922 | ||||||||||||||||||
Diluted earnings per share | $ | 0.15 | $ | 0.45 |
Silicon Laboratories Inc. Condensed Consolidated Balance Sheets (In thousands, except per share data) (Unaudited) |
||||||||
September 28,
2013 |
December 29,
2012 |
|||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 116,539 | $ | 105,426 | ||||
Short-term investments | 153,857 | 176,565 | ||||||
Accounts receivable, net of allowances for doubtful accounts of
$717 at September 28, 2013 and $670 at December 29, 2012 |
68,499 | 78,023 | ||||||
Inventories | 44,817 | 49,579 | ||||||
Deferred income taxes | 17,356 | 16,652 | ||||||
Prepaid expenses and other current assets | 51,097 | 41,437 | ||||||
Total current assets | 452,165 | 467,682 | ||||||
Long-term investments | 10,671 | 11,369 | ||||||
Property and equipment, net | 134,398 | 135,271 | ||||||
Goodwill | 227,289 | 130,265 | ||||||
Other intangible assets, net | 136,054 | 90,750 | ||||||
Other assets, net | 39,150 | 36,629 | ||||||
Total assets | $ | 999,727 | $ | 871,966 | ||||
Liabilities and Stockholders’ Equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 24,885 | $ | 29,622 | ||||
Current portion of long-term debt | 5,000 | 5,000 | ||||||
Accrued expenses | 42,639 | 40,410 | ||||||
Deferred income on shipments to distributors | 29,876 | 30,259 | ||||||
Income taxes | 1,457 | 1,087 | ||||||
Total current liabilities | 103,857 | 106,378 | ||||||
Long-term debt | 91,250 | 95,000 | ||||||
Other non-current liabilities | 70,342 | 20,615 | ||||||
Total liabilities | 265,449 | 221,993 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Preferred stock--$0.0001 par value; 10,000 shares authorized; no
shares issued and outstanding |
-- | -- | ||||||
Common stock--$0.0001 par value; 250,000 shares authorized;
43,093 and 41,879 shares issued and outstanding at September 28, 2013 and December 29, 2012, respectively |
4 | 4 | ||||||
Additional paid-in capital | 55,085 | 10,122 | ||||||
Retained earnings | 679,970 | 640,793 | ||||||
Accumulated other comprehensive loss | (781 | ) | (946 | ) | ||||
Total stockholders' equity | 734,278 | 649,973 | ||||||
Total liabilities and stockholders' equity | $ | 999,727 | $ | 871,966 |
Silicon Laboratories Inc. Condensed Consolidated Statements of Cash Flows (In thousands) (Unaudited) |
||||||||
Nine Months Ended | ||||||||
September 28,
2013 |
September 29,
2012 |
|||||||
Operating Activities | ||||||||
Net income | $ | 39,177 | $ | 44,853 | ||||
Adjustments to reconcile net income to cash provided by operating activities: | ||||||||
Depreciation of property and equipment | 10,050 | 10,247 | ||||||
Net gain on the purchase of property and equipment | -- | (8,457 | ) | |||||
Amortization of other intangible assets and other assets | 11,051 | 11,001 | ||||||
Stock-based compensation expense | 22,304 | 23,796 | ||||||
Income tax benefit (detriment) from employee stock-based awards | (621 | ) | 2,301 | |||||
Excess income tax benefit from employee stock-based awards | (284 | ) | (2,470 | ) | ||||
Deferred income taxes | 6,790 | 5,024 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 12,599 | (18,470 | ) | |||||
Inventories | 6,213 | (5,994 | ) | |||||
Prepaid expenses and other assets | (1,606 | ) | 13,283 | |||||
Accounts payable | (3,017 | ) | 9,113 | |||||
Accrued expenses | (2,864 | ) | (797 | ) | ||||
Deferred income on shipments to distributors | (3,169 | ) | 5,267 | |||||
Income taxes | (1,429 | ) | (4,378 | ) | ||||
Net cash provided by operating activities | 95,194 | 84,319 | ||||||
Investing Activities | ||||||||
Purchases of available-for-sale investments | (164,317 | ) | (138,822 | ) | ||||
Proceeds from sales and maturities of available-for-sale investments | 186,936 | 209,972 | ||||||
Purchases of property and equipment | (8,984 | ) | (99,720 | ) | ||||
Purchases of other assets | (3,499 | ) | (6,146 | ) | ||||
Acquisition of businesses, net of cash acquired | (86,441 | ) | (71,852 | ) | ||||
Net cash used in investing activities | (76,305 | ) | (106,568 | ) | ||||
Financing Activities | ||||||||
Proceeds from issuance of common stock, net of shares withheld for taxes | 11,900 | 3,035 | ||||||
Excess income tax benefit from employee stock-based awards | 284 | 2,470 | ||||||
Repurchases of common stock | (7,776 | ) | (51,040 | ) | ||||
Proceeds from issuance of long-term debt, net | -- | 98,325 | ||||||
Payments on debt | (12,184 | ) | -- | |||||
Net cash provided by (used) in financing activities | (7,776 | ) | 52,790 | |||||
Increase in cash and cash equivalents | 11,113 | 30,541 | ||||||
Cash and cash equivalents at beginning of period | 105,426 | 94,964 | ||||||
Cash and cash equivalents at end of period | $ | 116,539 | $ | 125,505 |